Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: < 0.0001). Efficacy was consistent across subgroups. Treatment-emergent adverse events occurred in 71.2% of Firsekibart-treated patients and 69.9% of those receiving CB. In conclusion, Firsekibart is effective and well tolerated for acute gout flares in patients unsuitable for standard therapy, demonstrating non-inferiority in rapid pain relief and significant superiority in preventing flare compared with CB.
Source: The Innovation
Authors: Yu Xue, Tianshu Chu, Jiankang Hu, Wei Gou, Ning Zhang, Juan Li, Jing Yu, Rongping Li, Rongbin Li, Long Qian, Xinwang Duan, Lihua Duan, Xu Zhang, Yuling Lian, Yi Li, Chuang Qi, Dongzhe Huang, Hejian Zou
Institutions: Fudan University, Huashan Hospital, Henan Provincial People's Hospital, Jiangxi Pingxiang People's Hospital, Sheng Jing Hospital, China Medical University, Hainan Medical University, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, First Affiliated Hospital of Gannan Medical University, Anhui Medical University, Second Affiliated Hospital of Anhui Medical University, Second Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hospital
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,000
OpenAlex ID: W4412055351